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Abstract
The bone morphogenetic protein (BMP) signaling pathway has essential functions in
development, homeostasis, and in the normal and pathophysiologic remodeling of tissues. Small
molecule inhibitors of the BMP receptor kinase family have been useful for probing physiologic
functions of BMP signaling in vitro and in vivo, and may have roles in the treatment of BMP-
mediated diseases. Here we describe the development of a selective and potent inhibitor of the
BMP type I receptor kinases, LDN-212854, which in contrast to previously described BMP
receptor kinase inhibitors exhibits nearly 4 orders of selectivity for BMP versus the closely related
TGF-β and Activin type I receptors. In vitro, LDN-212854 exhibits some selectivity for ALK2 in
preference to other BMP type I receptors, ALK1 and ALK3, which may permit the interrogation
of ALK2-mediated signaling, transcriptional activity and function. LDN-212854 potently inhibits
heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia
ossificans progressiva. These findings represent a significant step towards developing selective
inhibitors targeting individual members of the highly homologous BMP type I receptor family.
Such inhibitors would provide greater resolution as probes of physiologic function, and improved
selectivity against therapeutic targets.
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Introduction
Bone morphogenetic protein (BMP) signaling plays major roles in embryonic patterning,
tissue remodeling, and maintaining physiologic homeostasis (1). It has become increasingly
appreciated that disordered BMP signaling contributes to developmental and postnatal
disease (2, 3). BMPs belong to the transforming growth factor beta (TGF-β) superfamily of
signaling ligands that consist of more than 25 different ligands including TGF-βs, growth
and differentiation factors, and Activins (1, 4). BMP ligand dimers facilitate the assembly of
tetrameric receptor complexes composed of two constitutively-active type II receptor serine-
threonine kinases (BMPRII, ACTRIIA, or ACTRIIB) that transphosphorylate and activate
two type I receptor serine-threonine kinases (ALK1, ALK2, ALK3, or ALK6) (Figure 1a).
Activated type I receptors phosphorylate BMP receptor responsive SMAD proteins 1, 5, or
8, which in association with co-SMAD4 translocate to the nucleus to regulate gene
transcription (4). Activin and TGF-β ligands similarly recruit TGF-β or Activin type II
receptors (TGFβR2, ACTRIIA, or ACTRIIB) with a set of type I receptors (ALK4, ALK5,
or ALK7) to activate SMADs 2 and 3, which translocate with SMAD4 to the nucleus to
regulate distinct transcriptional programs.
Specificity in BMP and TGF-β signaling is conferred in part by preferential binding of
ligands with specific combinations of type I and type II receptors, although there is
considerable functional redundancy among ligands and receptors (5). Biological context is
provided by the spatiotemporally regulated expression of ligands and their cognate receptors
in target tissues (6). The diversity of upstream ligand and receptors signals, and their
pleiotropic downstream effects raises questions of how specificity is recognized and
translated into biological outcome in this pathway (7). Targeting individual ligands and
receptors by genetic epistasis has yielded important insights into function, but their
interpretation is limited again by redundancy as well as embryonic effects. Pharmacologic
strategies for modulating BMP and TGF-β signaling have emerged as a promising strategy
for elucidating function and specificity in these pathways. These strategies include small
molecule kinase inhibitors and recombinant protein ligand-traps (3).
A common challenge to the development of selective ATP competitive small molecule
kinase inhibitors is the structural homology of highly conserved ATP binding domains (8).
Structural homology is particularly high between the type I receptors of the BMP and TGF-β
signaling pathways. For example, the ALK3 kinase domain possesses 66% sequence identity
with that of ALK5 (9). Even greater kinase domain sequence identity is found between
homologues within the BMP or TGF-β families, such as ALK1 and ALK2 (79%), ALK3
and ALK6 (86%), and ALK4 and ALK5 (90%). The high degree of structural homology
between receptors poses serious challenges for the development of highly selective small
molecules that can discriminate between the individual members of the TGF-β or BMP
receptor families.
Highly selective inhibitors could be useful as therapeutics for diseases mediated by
inappropriate signaling of an individual type I receptor, exemplified best by fibrodysplasia
ossificans progressiva (FOP), an extremely rare genetic disease with a worldwide prevalence
of 1 in 2 million (10). FOP manifests generally within the first decade of life with episodic
soft tissue lesions that progress to ectopic endochrondral bone within skeletal muscles,
ligaments and fascia, resulting in severely impaired mobility and shortened life expectancy
(11). The majority of FOP cases are caused by a highly conserved missense mutation in
ACVR1 encoding the BMP type I receptor ALK2 (c.617G>A; p.R206H) (10). Crystal
structures of ALK2 have revealed that FOP mutations affecting the glycine-serine (GS-) rich
regulatory domain disrupt stabilizing interactions with the regulatory protein FKBP12,
rendering the kinase constitutively active with inappropriate downstream signaling.(12, 13)
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Possessing a constitutively-active intracellular kinase, ALK2R206H is unlikely to be affected
by endogenous antagonists of BMP signaling such as chordin or noggin, which sequester
BMP ligands, or similar ligand-traps. ALK2R206H thus represents an ideal therapeutic target
for a highly selective small molecule kinase inhibitor as a treatment for FOP.
We previously described the identification of a small molecule BMP inhibitor,
dorsomorphin, and the development of a highly potent derivative, LDN-193189, based on
the same pyrazolo[1,5-a]pyrimidine core structure (14, 15). LDN-193189 reduced
heterotopic ossification (HO) in a mouse model of FOP with an inducible constitutively
active mutant ALK2Q207D (caALK2) transgene (16). LDN-193189 is a potent inhibitor of
BMP signaling, but exhibits TGF-β receptor inhibition at higher concentrations. Previously
well-described small molecule inhibitors of the TGF-β type I receptor kinases, such as
A-83-01 and SB-505124, have both high potency and high (≥ 3 log) selectivity for TGF-β
versus BMP signaling (17, 18). While TGF-β signaling inhibitors had potential utility as
therapeutic agents, preclinical animal studies have associated the administration of highly
potent ALK5 inhibitors with bone physeal abnormalities in immature animals, and
hemorrhagic necrosis of heart valves in adult animals (19, 20). Clinically viable BMP
receptor kinase inhibitors, particularly for indications requiring long term treatment, may
need to minimize or eliminate off-target inhibition of the TGF-β and Activin type I receptor
kinases, ALK4, ALK5, and ALK7 in light of these toxicities.
Here we describe the development of LDN-212854 a novel BMP inhibitor that exhibits
substantially greater selectivity for BMP versus the TGF-β type I receptors. In addition,
LDN-212854 possesses a bias towards ALK2 versus ALK1 and ALK3 compared to other
inhibitors. LDN-212854 supports the concept that development of selective inhibitors of
individual type I receptors may be feasible despite the high degree of homology between
these receptors. LDN-212854 provides useful selectivity in vitro for resolving ALK2 versus
ALK3 signaling as shown in cellular assays of hepcidin expression and osteogenic
differentiation. In addition, LDN-212854 provides comparable potency in a mutant ALK2
transgenic mouse model of FOP to LDN-193189. LDN-212854 or similar compounds that
selectively target individual BMP receptors can be used in vitro to ascertain individual
receptor functions, and may have favorable characteristics as clinical candidates.
RESULTS and DISCUSSION
SAR of modified pyrazolo-pyrimidines
To alleviate toxicity concerns associated with TGF-β inhibition and to develop improved
tools for understanding BMP signaling, we determined the structure-activity relationship
(SAR) of pyrazolo[1,5-a]pyrimidine derivatives with varied quinoline attachment positions
(Figure 1b-c). We previously assayed this set of derivatives using a cell-based BMP4-
induced SMAD 1/5/8 phosphorylation in cell western assay (15). However, since BMP4 has
been shown to preferentially bind to ALK3, this assay was likely biased towards inhibitors
of ALK3 (21). To overcome these limitations we developed a highly sensitive cell-free
enzymatic assay using recombinant BMP and TGF-β type I receptor kinases (ALK1, ALK2,
ALK3, ALK4, and ALK5) that could detect the activity of ~ 1 nM kinase protein. The
resulting SAR demonstrated that 3, 8, and 6-quinoline substituted derivatives had little
activity against either BMP or TGF-β type I receptors (Figure 1b). However, the 5-quinoline
derivative LDN-193719 exhibited improved BMP versus TGF-β selectivity compared to the
4-quinoline derivative LDN-193688 (550-fold versus 60-fold selectivity, Figure 1d).
LDN-193719 also demonstrated greater potency against ALK2 (IC50 = 44 nM) than ALK3
(IC50 = 1.5 μM), providing a potential explanation of the weak inhibition of BMP4-induced
signaling previously observed by in-cell western assay (15). To determine if increased
selectivity for BMP versus TGF-β and particularly ALK2 might be generalizable to other 5-
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quinoline-substituted compounds, LDN-212854 was synthesized by combining the 5-
quinoline moiety of LDN-193719 with the phenyl-piperazine substituent of LDN-193189.
The synthetic scheme and compound characterization of LDN-212854 are provided in the
Supporting Information.
Characterization of BMP Inhibitors
We profiled the selectivity of the known inhibitors of BMP signaling dorsomorphin,
LDN-193189, DMH1, the 2-aminopyridine inhibitor K02288a, and our novel pyrazolo[1,5-
a]pyrimidine 5-quinoline derivative LDN-212854 (Figure 2a) (22, 23). Based on the above
SAR data, we hypothesized that the 5-quinoline derivative might improve selectivity for the
BMP pathway, while maintaining potency. All inhibitors tested primarily targeted the BMP
type I receptors, particularly the highly homologous receptors ALK1 and ALK2 (Figure 2b).
Importantly, whereas other investigators have assayed inhibition of BMP receptor kinase
activity using ≥ 100 nM enzyme (22), resulting in the lowest measurement of IC50 being
bounded by half the active enzyme concentration (e.g. ~ 50 nM), we used 2.5 nM of purified
kinase in this radiometric assay, permitting the measurement IC50 values substantially lower
than those previously reported. For example, Vogt et al. reported an in vitro IC50 of 45 nM
for LDN-193189 against ALK2, as compared to an IC50 of approximately 0.7 nM for ALK2
in our assay (24). Among compounds tested, LDN-193189 was the most potent inhibitor of
ALK2, followed closely by both K02288a and LDN-212854 (both with IC50 ~ 1.2 nM).
Compared to these potent compounds, dorsomorphin and DMH1 were weaker by
approximately 10-fold. While LDN-193189 and K02288a inhibited the TGF-β type I
receptor ALK5 with approximate IC50 measurements of 110 nM and 230 nM, respectively,
whereas LDN-212854 inhibited ALK5 in the micromolar range, and thus had substantially
greater selectivity for ALK2 versus ALK5 (Figure 2c–d). The selectivity for BMP versus
TGF-β signaling, based on the ratio of the IC50 for the inhibition of ALK5 to ALK2, was
approximately 7000-fold for LDN-212854, as compared to 800-fold, 175-fold, 470-fold, and
200-fold for dorsomorphin, LDN-193189, DMH1, and K02288, respectively (Figure S1).
Thus, in a kinase inhibition assay using lower kinase concentrations than previously
described, LDN-212854 demonstrated much greater selectivity for BMP versus TGF-β type
I receptors than other compounds while retaining nanomolar potency.
To confirm kinase assay results in cellular assays of BMP- and TGF-β-induced
transcriptional activity, we used C2C12 cells stably expressing BMP responsive (BRE-Luc)
and 293T cells stably expressing TGF-β responsive (CAGA-Luc) luciferase reporter
transgenes (see Supporting Methods) (25, 26). Cells were transfected with adenoviruses
expressing constitutively-active BMP type I receptors (caALK1, caALK2, and caALK3) and
constitutively active TGF-β type I receptors (caALK4 and caALK5) in low serum conditions
and in the absence of exogenous ligand, with varying concentrations of inhibitors.
LDN-193189 was the most potent inhibitor of BMP signaling (IC50 ~ 11 nM for caALK2).
LDN-193189 inhibited caALK5 with an IC50 ~ 213 nM, demonstrating ~20-fold selectivity
for caALK2 versus caALK5 in cells (Figure 3a). Dorsomorphin was less potent than
LDN-193189, and exhibited approximately 9-fold selectivity for caALK2 vs. caALK5.
While the cellular assay results for these two compounds aligned closely with those obtained
using the kinase assay, the activity of DMH1 and K02288a differed significantly between
kinase and cell-based assays. DMH1 was a relatively weak inhibitor of caALK2 in cells
(IC50 ~ 230 nM) and had greater activity against caALK5 signaling (IC50 ~ 700 nM) than
might be expected based on kinase assay results. Thus, the selectivity of DMH1 for caALK2
vs. caALK5 was only 2.5-fold in cells versus 470-fold in kinase assays. These cell-based
IC50 data confirmed that DMH1 is a less potent inhibitor of BMP signaling than
LDN-193189 (22), however, DMH1 did not significantly improve selectivity for BMP
versus TGF-β. Despite data suggesting similar potency to LDN-193189 in kinase assays,
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K02288a was significantly less potent in cells, inhibiting both caALK2 (IC50 ~ 225 nM) and
caALK5 (IC50 ~ 700 nM) modestly and without the same degree of selectivity observed in
kinase assays (~ 3-fold vs. 200-fold).
In contrast, the BMP selectivity of LDN-212854 demonstrated in the kinase assay was
confirmed in cells with an IC50 for caALK2 of 16 nM and an IC50 for caALK5 of
approximately 2 μM, resulting in more than 130-fold selectivity for caALK2 vs. caALK5
(Figure 3a and S1). Representative inhibition curves for dorsomorphin, LDN-193189,
LDN-212854, K02288a, and DMH1 against constitutively active BMP and TGF-β type I
receptors also demonstrated the improved selectivity of LDN-212854 (Figure S2). At 100
nM, LDN-212854 inhibited 98% of caALK2-mediated signaling while exerting minimal
effect on caALK4 or caALK5, whereas all other compounds inhibited caALK4 and caALK5
significantly at concentrations required to suppress caALK2 signaling to the same degree
(Figures 3b–c and S2). In addition to having improved selectivity for caALK2 versus
caALK5, LDN-212854 demonstrated a bias towards caALK2 within the BMP type I
receptor family. LDN-212854 inhibited caALK2 with 6- and 10-fold more potency than
caALK1 or caALK3, respectively (Figure S1).
To confirm results obtained using constitutively-active type I receptors, we tested the
selectivity of LDN-193189 and LDN-212854 against specific BMP and TGF-β ligands. We
examined the impact of inhibitors upon BMP7-induced (20 ng mL−1, 30 min.) activation of
SMAD1/5/8 using BMPR2-deficient pulmonary vascular smooth muscle cells, which we
have previously found to use ALK2 almost exclusively for the transduction of BMP7
signaling (27). We used TGF-β1 ligand (5 ng mL−1, 30 min) to induce TGF-β signaling and
phosphorylation of SMAD2. In this ligand-based cellular assay, LDN-212854 and
LDN-193189 exhibited comparable, low nanomolar potency in blocking the
phosphorylation of SMAD1/5/8 induced by BMP7 in BMPR2−/− cells (Figure 4a).
Importantly, the selectivity of LDN-212854 for BMP versus TGF-β signaling was even
greater than that observed using constitutively active type I receptors, with almost no
inhibition of TGF-β1 signaling at the highest concentration tested (25 μM, Figure 4b), in
contrast to significant effects observed above 1 μM for LDN-193189. These ligand-
mediated signaling assays confirmed that LDN-212854 inhibits BMP versus TGF-β
signaling with nearly 4-log selectivity, much greater than previously described BMP
inhibitors and comparable to the selectivity of A-83-01 for TGF-β versus BMP signaling
(17).
LDN-212854 preferentially inhibits ALK2
In addition to inhibiting caALK2 more potently than caALK4 and caALK5 in cell based
assays, LDN-212854 also exhibited approximately one log selectivity for caALK2 versus
caALK3. When C2C12 cells were transfected with caALK2, both LDN-193189 and
LDN-212854 inhibited BMP transcriptional activity (BRE-Luciferase) with comparable low
nanomolar efficacy (Figure 5a). When C2C12 cells were transfected with constitutively
active ALK3, LDN-193189 was nearly 14-fold more potent than LDN-212854 (11 nM
versus 153 nM, Figure 5b). We tested whether or not the selectivity of LDN-212854 for
caALK2 versus caALK3 could be used to discriminate between the utilization of these
receptors in two biological assays. First, we examined the impact of compounds on the
BMP-induced osteogenic differentiation of myofibroblast C2C12 cells. When C2C12 cells
were stimulated with BMP4 or BMP6 (20 ng mL−1, 6 d), osteogenic differentiation assayed
by alkaline phosphatase (ALP) activity was observed. In this system, BMP6 has been shown
to function primarily via ALK2, whereas BMP4 interacts primarily with ALK3 to induce
ALP (21, 28). As predicted based on assays using caALK2 and caALK3, LDN-193189
inhibited both BMP6- and BMP4-induced ALP with comparable low-nanomolar potency
(IC50 ~ 5 nM, Figure 5c–d). In contrast, LDN-212854 inhibited BMP6-induced ALP
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expression more potently than BMP4 (IC50 ~ 10 nM versus 40.5 nM). Thus, LDN-212854
exhibited greater selectivity for BMP6- versus BMP4-induced osteogenic differentiation
consistent with its preference for ALK2 versus ALK3.
Next, we used LDN-212854 to probe IL-6-induced expression of hepcidin in HepG2
hepatoma cells. The in-vitro induction of hepcidin in this assay models the homeostatic
pathway governing serum iron levels mediated by the BMP- and IL-6-regulated expression
of hepcidin in the liver. In anemia of inflammation, IL-6 mediated signaling is thought to
enhance hepcidin regulation in a BMP6-dependent fashion, inactivating iron transporter
ferroportin and thereby decreasing circulating iron bioavailability for erythropoiesis (29,
30). The dose-dependent impact of LDN-193189 and LDN-212854 upon IL-6-induced (100
ng mL−1, 90 min.) expression of hepcidin mRNA was measured in cells by quantitative RT-
PCR (Figure 5e). We have previously shown that ALK3 is the dominant BMP type I
receptor required for IL-6-induced hepcidin expression in vitro and in vivo (31). Stimulation
with IL-6 alone resulted in an 18-fold increase in hepcidin expression over control. Co-
treatment with IL-6 and either LDN-193189 or LDN-212854 resulted in the inhibition of
hepcidin mRNA expression (with approximate IC50 values of 5 nM and 125 nM,
respectively, Figure 5e). The relatively weaker inhibition of IL-6-mediated hepcidin
expression by LDN-212854 correlated with its weaker inhibition of ALK3 compared to
LDN-193189 (Figure 5a-b), and supported the concept that ALK3 is the principal receptor
responsible for IL-6-regulated hepcidin expression. As previously observed, maximum
inhibition with either LDN-193189 or LDN-212854 did not reduce hepcidin expression to
levels of controls, suggesting BMP-independent signaling mechanisms may also contribute
to IL-6 induced hepcidin expression (32). Taken together these results demonstrate that
LDN-212854 can provide some useful albeit limited resolution of signaling via ALK2
versus other BMP receptors in vitro. It is unlikely that LDN-212854 would discriminate the
activity of ALK2 in vivo, in part due to wide ranging plasma concentrations during
absorption and metabolism, but subsequent derivatives with greater selectivity might be
useful in vivo probes of ALK2 function.
LDN-212854 inhibits ALK2Q207D-induced HO
To demonstrate the in vivo efficacy of LDN-212854, we employed a murine inducible
transgenic ALK2Q207D model of heterotopic ossification (see Supporting Methods) (16).
Intramuscular injection of Ad. Cre potently induces recombination of a floxed inducible
ALK2Q207D and a GFP reporter, while inducing myositis and necrosis. This combination of
inflammation and mutant ALK2 expression result in ectopic endochondral bone lesions
reminiscent of FOP. Following retropopliteal injection of Ad. Cre (108 pfu on P7), mice
were treated for 4 weeks with vehicle, LDN-193189 or LDN-212854 (6 mg kg−1, I.P., twice
daily). Heterotopic bone was assayed by x-ray, and alizarin red and alcian blue staining,
while GFP expression was used to confirm recombination of the ALK2Q207D transgene at
the injection sites (Figure 6a-c). Bone formation and corresponding hindlimb immobility
was 100% penetrant in vehicle treated mice as measured by passive range of motion scores
(Figure 6d). LDN-193189 and LDN-21285 treatment prevented the formation of heterotopic
bone and preserved limb range of motion with minimal or no impairment in the majority of
mice. These results demonstrate that LDN-212854 can effectively neutralize ALK2
signaling in vivo. By virtue of increased BMP selectivity, 5-quinoline substituted
pyrazolo[1,5a-]pyrimidine compounds such as LDN-212854 could be advantageous for the
treatment of FOP by minimizing toxicity due to inhibition of TGF-β type I receptors.
Kinase profiling
Given the highly conserved nature of the kinase domain across the human kinome, many
ATP-competitive kinase inhibitors exhibit significant off-target effects (33). The off-target
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effects of LDN-193189 and LDN-212854 were determined against a panel of 198 kinases
broadly representing the human kinome (Figure 7 and Supporting Information). Compounds
were tested at 100 nM, a concentration chosen based on the high potency of these
compounds against ALK2, and at 1 μM, a standard concentration for profiling off-target
activities. While the 5-quinoline moiety of LDN-212854 greatly increased BMP versus
TGF-β selectivity, it did not improve kinome wide selectivity. The IC50 values of
LDN-193189 and LDN-212854 against several of these kinases were determined revealing
significant activity against RIPK2, ABL1, and PDGFR-β (IC50 < 100 nM) whereas the IC50
values for PDGFR-α, VEGFR2 and KIT were greater than 300 nM (Figure 7a). These data
confirm a recent report that RIPK2, in particular, appears to be a principal off-target liability
of LDN-193189 with an IC50 comparable to that of ALK2.(24) Thus LDN-212854 and
LDN-193189, when used in the low nanomolar range (≤100 nM), would effectively inhibit
BMP signaling while minimizing effects against most kinases, except RIPK2. The use of
LDN-193189 or LDN-212854 to inhibit BMP signaling should consider these off-target
effects and particularly RIPK2, known to have important roles in modulating innate
immunity and inflammation (34, 35).
Inhibitor binding mode
To gain insight into its improved selectivity compared to LDN-193189, the binding mode of
LDN-212854 to ALK2 was investigated by a molecular modeling approach, using the
available co-structure of LDN-193189 as a template (36). In this complex, the pendant 4-
quinoline moiety formed an important water-mediated hydrogen bond to the αC-helix
residue E248 (Figure 8a). Significantly, this bond is lost upon substitution of the 5-quinoline
group in LDN-212854 (Figure 8b). Instead, a new water-mediated hydrogen bond to the
catalytic lysine residue K235 is predicted, as previously observed in the ALK2-K02288
structure (23). E248 and K235 are strictly conserved residues that form a necessary ion pair
in all active kinases (for example, ALK5 residues E245 and K232). Therefore, sequence
alone cannot explain the reduced binding of LDN-212854 to ALK5. However, inspection of
the available ALK5 structures reveals a subtle shift in the orientation of the αC-helix and a
conserved water molecule that is shifted to a deeper location in the ATP pocket bound
between ALK5 E245 and Y249 (Figure 8c). This water molecule appears favorable for
hydrogen bonding to the 4-quinoline of LDN-193189, but not to the 5-quinoline moiety of
LDN-212854, potentially explaining the relatively poor inhibition of ALK5 by
LDN-212854.
Conclusion
We used highly specific and sensitive assays of BMP and TGF-β type I receptor signaling to
characterize in detail several known BMP signaling inhibitors as well as a novel compound
with improved selectivity for BMP versus TGF-β signaling, LDN-212854. While it does not
improve kinome-wide selectivity compared to LDN-193189, LDN-212854 is notable
because it preferentially targets ALK2 at substantially lower concentrations than other BMP
type I receptors. Previously described inhibitors of the BMP signaling pathway based on
dorsomorphin (LDN-193189, DMH1) or other scaffolds (K02288a) exhibit substantial
cross-reactivity with type I receptors of the TGF-β signaling pathway, potentially limiting
their utility as biological probes, as well as therapeutic agents due to the known toxicities of
ALK5 inhibitors (2, 7). At concentrations of 30-100 nM LDN-212854 demonstrated nearly
complete inhibition of ALK2 without significant impact on Activin and TGF-β receptors
(Figure S1). LDN-212854 represents a significant step towards developing compounds that
target individual receptors of the BMP signaling pathway, a goal previously thought to be
limited by the high degree of structural homology between these receptors, ALK1, ALK2,
ALK3 and ALK6 (9).
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While we and others have demonstrated the utility of several of these compounds as
biological probes in vitro and in vivo, the accurate interpretation of such experiments using
small molecule kinase inhibitors requires careful consideration of their potency, selectivity,
and off-target effects. Due to the increased sensitivity of our kinase assays, we could detect
differences in compound potency at concentrations approaching 1 nM, a measurement that
was limited in previous reports by the use of higher (≥ 100 nM) concentrations of active
kinase (22, 24). The ability to resolve these important differences in activity allowed us to
identify compounds such as LDN-212854 with preserved low nanomolar activity against
ALK2 but decreased activity against other type I receptors. We found that compounds
DMH1 and K02288 exhibited potent and selective inhibition of BMP type I receptors in
kinase assays, but were less potent and selective in cell-based assays of BMP signaling. The
decreased activity of these compounds in cells might be due to limited stability or membrane
permeability, an interpretation that could be explored with further characterization and
medicinal chemistry optimization. DMH1 was previously reported to have less activity than
dorsomorphin and LDN-193189 against tyrosine kinase receptors such as VEGFR2 (22).
Similarly, we found that LDN-212854 also had decreased activity against VEGFR2 (2.8
μM) than LDN-193189 (0.56 μM, Figure 7a).
The current data provide further clarity on the appropriate use of known BMP inhibitors and
introduce a novel compound that is highly selective for BMP receptors with a bias towards
ALK2. Given the broad developmental and homeostatic roles of receptors of the BMP
receptor family, maximizing the selectivity of compounds for specific receptors of interest
could be advantageous for their use in therapy, a goal that could be effectively pursued with
further structural modeling and medicinal chemistry. Monoselective compounds targeting
individual BMP type I receptors could yield substantial new insights into the complex
physiology of this receptor pathway. The selectivity of LDN-212854 makes this compound a
useful reagent for interrogating ALK2 signaling in vitro, and provides a potential template
for the development of clinical compounds for treating ALK2-mediated disease such as
FOP.
METHODS
Kinase Assay
Purified recombinant ALK1-5 and other kinase proteins (Invitrogen), ATP (Sigma), ATP
[γ-32P] (Perkin Elmer), and dephosphorylated casein (Sigma) at final concentrations of
2.5nM, 6μM, 0.05 μCi μL−1, and 0.5 mg mL−1 respectively were aliquoted in kinase buffer
(Cell Signaling) containing 0.2% bovine serum albumin supplemented with 10mM MnCL2
into 96-well plates, in combination with inhibitor compounds diluted at varying
concentrations in kinase buffer (0.01nM to 10 μM) in triplicate. Positive control samples
lacking inhibitor compounds, and negative controls lacking recombinant kinase were also
measured in triplicate. The mixture was reacted at RT for 45 min., quenched with a final
concentration of 2% phosphoric acid. The reaction mixture was transferred to 96-well P81
phosphocellulose filter plates (Millipore) and bound for 5 min. The plates were washed
twenty-times with 150 μL of 1% phosphoric acid solution per well by vacuum manifold.
Plates were dried at RT for 1 h, sealed, and assayed with Microscint 20 scintillation fluid
(Perkin Elmer) using a Spectramax L luminometer (Molecular Devices) using the photon
counting setting with an integration time of one second per well. Data was normalized to
positive controls at 100% enzyme activity with negative controls being subtracted as
background. GraphPad (Prism software) was used for graphing and regression analysis by
sigmoidal dose-response with variable Hill coefficient.
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Luciferase Reporter Assay
C2C12 myofibroblasts cells stably transfected with BMP responsive element from the Id1
promoter fused to luciferase reporter gene (BRE-Luc) were generously provided by Dr.
Peter ten Dijke (Leiden University Medical Center, NL) (25). Human embryonic kidney
293T cells stably transfected with the TGF-β responsive element from the PAI-1 promoter
fused to luciferase reporter gene (CAGA-Luc) were generously provided by Dr. Howard
Weiner (Brigham and Women’s Hospital, Boston, MA) (26). C2C12 Bre-Luc and 293T
CAGA-Luc cells were seeded at 20,000 cells in DMEM supplemented with 2% FBS per
well in tissue culture treated 96-well plates (Costar® 3610; Corning). The cells were
incubated for 1 h (37°C and 10% CO2) and allowed to settle and attach. Compounds of
interest or DMSO were diluted in DMEM and added at final compound concentrations of 1
nM to 10 μM. Cells were then incubated for 30 min. Adenovirus expressing constitutively
active BMP and TGF-β type I receptors (Ad.caALK1-5), generously provided by Dr. Akiko
Hata (University of California at San Francisco), were added to achieve a multiplicity of
infection (MOI) of 100. Plates were incubated overnight at 37°C. Cell viability was assayed
with an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) colorimetric
assay (Promega) per the manufacturer’s instructions. Media was discarded, and firefly
luciferase activity was measured (Promega) according to manufacturer’s protocol. Light
output was measured using a Spectramax L luminometer (Molecular Devices) with an
integration time of one second per well. Data was normalized to 100% of incremental BRE-
Luc activity due to adenoviruses specifying caALK1, 2, or 3, or the incremental CAGA-Luc
activity due to adenoviruses specifying caALK4 or 5. Graphing and regression analysis by
sigmoidal dose-response with variable Hill coefficient was performed using GraphPad Prism
software.
BMP Induced ALP Activity
C2C12 myofibroblasts cells were seeded in 96-well plates (Corning) at 2,000 cells per well
in DMEM supplemented with 2% FBS as previously described (37). Compounds diluted in
DMEM and were added at final concentrations ranging from 1nM to 10 μM, in
quadruplicate. BMP4 and BMP6 ligands diluted in DMEM were added to final
concentrations of 20 ng mL−1. Positive controls were generated by omitting compounds and
negative controls were generated by omitting both compounds and ligands. Cells were
incubated for 6 days at 37°C and 5% CO2 and subsequently harvested using 1% Triton
X-100. Extracts from each well were incubated at RT for 30 min with alkaline phosphatase
(ALP) yellow (pNPP) liquid substrate for ELISA (Sigma-Aldrich) and ALP activity was
measured by absorbance at 405 nM per the manufacturer’s instructions. Absorbance data
was analyzed with positive controls as 100% ALP activity and negative controls being
subtracted as background. Graphing and regression analysis by sigmoidal dose-response
with variable Hill coefficient was performed using GraphPad Prism.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Structure activity relationship of 4-methoxyphenyl pyrazolo[1,5-a]pyrimidine derivatives. a)
A schematic representation of the canonical BMP and TGF-β signaling pathways. b) In vitro
kinase assay IC50 measurements against BMP and TGF-β type I receptors show only the 4-
quinoline (LDN-193688) and 5-quinoline (LDN-193719) derivatives are active. c) Structure
of five pyrazolo[1,5-a]pyrimidine derivatives with varying quinoline attachment site. d) Fold
selectivity of active inhibitors against ALK2 versus BMP and TGF-β type I receptors.
Although slightly less potent against ALK2 than LDN-193688, the 5-quinoline derivative
LDN-193719 has much greater selectivity for BMP vs. TGF-β type I receptors.
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Figure 2.
Potency and selectivity of BMP inhibitors based on in vitro kinase assay. a) Structure of
previously described BMP inhibitors and LDN-212854. b) In vitro kinase assay
measurements of IC50 for BMP and TGF-β type I receptors show LDN-193189 is the most
potent inhibitor of ALK2, followed closely by K02288a and LDN-212854. Both DMH1 and
dorsomorphin exhibited 10-fold lower potency against BMP type I receptors. c) Fold
selectivity of these inhibitors against ALK2 versus closely related BMP and TGF-β type I
receptors. d) Inhibition of ALK2 (BMP) and ALK5 (TGF-β) kinase activity demonstrates
LDN-212854 exhibits increased selectivity for ALK2 versus ALK5. Data shown are
representative of 2-3 independent experiments.
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Figure 3.
Potency and selectivity of BMP inhibitors based on on BMP (BRe-Luc) and TGF-β (CAGA-
Luc) transcriptional activity mediated by constitutively active ALK1-5. a) In vitro cell-based
assay IC50 measurements against constitutively-active BMP (caALK1, 2, and 3) and TGF-β
(ALK4 and 5) type I receptors demonstrates LDN-212854 to be more selective for BMP
versus TGF-β receptors while retaining low nanomolar potency against caALK2. b–c)
Inhibition of caALK1-5 by BMP inhibitors at various concentrations demonstrates that
LDN-212854 preferentially inhibits caALK2 at concentrations near 100 nM, whereas other
receptors are affected at higher concentrations. Data shown are calculated based on IC50
generated from at least 3 independent experiments, with data plotted as mean ± S.E.M.
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Figure 4.
Comparison of potency and selectivity of LDN-193189 and LDN-212854 in modulating
BMP and TGF-β ligand-mediated SMAD signaling. a) Western blot analysis of BMP7
induced phosphorylation of SMAD1/5/8 in BMPR2−/− PASMCs reveals low nanomolar
inhibition by both LDN-193189 and LDN-212854. b) Western blot analysis of TGF-β1
induced phosphorylation of SMAD2 in wild-type PASMC revealed significant inhibition by
LDN-193189 at concentrations greater than 1 μM, and virtually no inhibition by
LDN-212854 at concentrations up to 25 μM. Data shown are representative of 2
independent experiments.
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Figure 5.
LDN-212854 provides useful selectivity as a probe of signaling mediated by ALK2 versus
ALK3, and their respective ligands. a) Representative inhibition curves of caALK2 and b)
caALK3 transcriptional activity (BRE-Luc) by LDN-193189 and LDN-212854 in C2C12
cells. Both compounds potently inhibit ALK2, whereas LDN-212854 is substantially weaker
against ALK3. c) Alkaline phosphatase (ALP) activity induced in C2C12 cells by BMP6,
which signals primarily through ALK2, was inhibited with comparable potency by
LDN-193189 and LDN-212854. d) ALP activity induced in C2C12 cells by BMP4, which
signals primarily through ALK3, was more potently inhibited by LDN-193189 than
LDN-212854. e) IL-6 induced hepcidin expression in HepG2 cells was inhibited potently by
LDN-193189 and less potently by LDN-212854, consistent with a primarily ALK3-
dependent mechanism of IL-6 induced hepcidin expression.
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Figure 6.
In vivo efficacy of LDN-212854 in a mouse model of fibrodysplasia ossificans progressiva
(FOP). Mice expressing an inducible constitutively-active ALK2Q207D (CAG-Z-EGFP-
caALK2) transgene were treated with a) vehicle, b) LDN-193189 or c) LDN-212854.
Heterotopic ossification following injection of Ad.Cre was observed by X-ray (top panels)
and staining for alizarin red and alcian blue (bottom panels). Heterotopic ossification
following Ad.Cre injection was observed 100% of vehicle-treated mice, whereas ossification
was essentially absent in mice treated with LDN-193189 or LDN-212854. Transgene-
mediated expression of GFP (middle panel) was observed at the site of Ad.Cre injection to
confirm recombination and ALK2Q207D expression. d) Passive range-of-motion was
progressively impaired in vehicle-treated mice starting on day 10, whereas mobility was
almost entirely preserved in mice treated with LDN-193189 and LDN-212854.
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Figure 7.
Kinase inhibition profile of LDN-193189 and LDN-212854. a) and b) Kinome dendrograms
for LDN-193189 and LDN-212854, respectively, showing both on-target hits from our
kinase assay and the top off-target hits from a screen of 198 human kinases. RIPK2 was the
most potently inhibited off-target kinase followed by ABL1 and PDGFR-β, while other
kinases were inhibited at much higher concentrations.
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Figure 8.
Predicted binding mode of LDN-212854. a) ATP pocket interactions of LDN-193189
(magenta) in the ALK2 co-structure (PDB 3Q4U). A single hydrogen bond to the hinge
residue H286 is made by the central pyrazolo[1,5-a] pyrimidine group. The pendant 4-
quinoline moiety forms a water-mediated hydrogen bond to the αC-helix residue E248.
Water is represented by a red sphere and labelled “Wat”. Hydrogen bonds are shown as a
dashed line. b) Model for the binding of LDN-212854 (green) to ALK2. The pendant 5-
quinoline group is predicted to form an alternative water-mediated hydrogen bond to the
catalytic lysine (K235). The new water position was modeled from the ALK2-K02288 co-
structure (PDB 3MTF). c) Model for the binding of LDN-193189 (magenta) to ALK5. The
inhibitor was located by the superposition of ALK2 (PDB 3Q4U) and ALK5 (SB-431542
complex; PDB 3TZM) (36). ALK5 structures show a conserved water position set further
back in the ATP pocket between the αC-helix residues E245 and Y249. This water can
mediate hydrogen bonding to the 4-quinolone of LDN-193189, but not to the 5-quinoline
moiety of LDN-212854, potentially explaining its poor binding.
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